Evaluation of bone marrow toxic reaction in patients treated with allopurinol
Proto-Oncogene Proteins B-raf
Receptor, Melanocortin, Type 1
To evaluate possible bone marrow toxic reaction related to allopurinol administration, 143 patients with malignant lymphoma were randomized to receive allopurinol for either three or six cycles of chemotherapy. There was no significant difference of nadir WBC or platelet counts. This trial failed to confirm an earlier study that suggested allopurinol increased the marrow toxic reaction of cytotoxic chemotherapy.